-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Trade Alert: The CEO & Executive Director Of Fusen Pharmaceutical Company Limited (HKG:1652), Zhiming Cao, Has Just Spent CN¥1.9m Buying 1.5% More Shares
Trade Alert: The CEO & Executive Director Of Fusen Pharmaceutical Company Limited (HKG:1652), Zhiming Cao, Has Just Spent CN¥1.9m Buying 1.5% More Shares
Investors who take an interest in Fusen Pharmaceutical Company Limited (HKG:1652) should definitely note that the CEO & Executive Director, Zhiming Cao, recently paid HK$0.96 per share to buy HK$1.9m worth of the stock. Although the purchase only increased their holding by 1.5%, it is still a solid purchase in our view.
See our latest analysis for Fusen Pharmaceutical
Fusen Pharmaceutical Insider Transactions Over The Last Year
Notably, that recent purchase by CEO & Executive Director Zhiming Cao was not the only time they bought Fusen Pharmaceutical shares this year. They previously made an even bigger purchase of HK$2.1m worth of shares at a price of HK$1.66 per share. That means that even when the share price was higher than HK$0.97 (the recent price), an insider wanted to purchase shares. It's very possible they regret the purchase, but it's more likely they are bullish about the company. We always take careful note of the price insiders pay when purchasing shares. It is encouraging to see an insider paid above the current price for shares, as it suggests they saw value, even at higher levels. Zhiming Cao was the only individual insider to buy during the last year.
Zhiming Cao purchased 12.44m shares over the year. The average price per share was HK$1.11. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
SEHK:1652 Insider Trading Volume September 11th 2022Fusen Pharmaceutical is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.
Insider Ownership Of Fusen Pharmaceutical
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Fusen Pharmaceutical insiders own about HK$347m worth of shares (which is 47% of the company). I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.
So What Does This Data Suggest About Fusen Pharmaceutical Insiders?
It is good to see the recent insider purchase. And an analysis of the transactions over the last year also gives us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. Along with the high insider ownership, this analysis suggests that insiders are quite bullish about Fusen Pharmaceutical. That's what I like to see! While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. At Simply Wall St, we've found that Fusen Pharmaceutical has 2 warning signs (1 doesn't sit too well with us!) that deserve your attention before going any further with your analysis.
But note: Fusen Pharmaceutical may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
感兴趣的投资者富森药业股份有限公司香港:1652)绝对应该注意到,董事首席执行官曹志明最近以每股0.96港元的价格购买了价值190万港元的该股。虽然此次收购只增加了他们1.5%的持股,但在我们看来,这仍然是一次坚实的购买。
查看我们对富森药业的最新分析
富森药业去年的内幕交易
值得注意的是,董事首席执行官曹志明最近的那次购买并不是他们今年唯一次购买富森制药的股票。此前,他们还以每股1.66港元的价格购入了价值210万港元的股票。这意味着,即使股价高于0.97港元(最近的价格),也有内部人士想要购买股票。他们很可能对收购感到后悔,但更有可能的是他们看好公司。我们总是仔细注意内部人士购买股票时支付的价格。看到内部人士支付高于当前股价的价格是令人鼓舞的,因为这表明他们看到了价值,即使是在更高的水平。曹志明是去年唯一被收购的个人内部人士。
曹志明在一年中购买了1244万股。每股平均价为1.11港元。你可以看到过去一年的内幕交易(由公司和个人),如下图所示。如果你想知道到底是谁卖了,卖了多少钱,什么时候卖的,只需点击下面的图表!
联交所:2022年9月11日内幕交易量1652富森药业并不是业内人士正在买入的唯一一只股票。所以让我们来看看这个免费内幕收购的成长型公司名单。
富森药业的内部人所有权
我喜欢看内部人士在一家公司持有多少股份,以帮助我了解他们与内部人士的关系。通常,内部人持股越高,内部人就越有可能受到激励,建立长期的公司。富森药业内部人士持有价值约3.47亿港元的股份(占该公司47%)。我喜欢看到这种程度的内部人持股,因为它增加了管理层考虑股东最佳利益的机会。
那么,这些数据对富森药业内部人士有什么启示呢?
很高兴看到最近的内幕收购。对过去一年交易的分析也给了我们信心。但另一方面,该公司在过去一年中出现了亏损,这让我们有点谨慎。除了高内部人持股,这一分析表明,内部人士相当看好富森制药。这就是我想看到的!虽然我们喜欢知道内部人士的所有权和交易情况,但在做出任何投资决定之前,我们也要确保考虑到一只股票面临的风险。在Simply Wall St.,我们发现富森药业2个警告标志(%1与我们的关系不太好!)在进一步分析之前,这一点值得你注意。
但请注意:富森药业可能不是最值得买入的股票。所以让我们来看看这个免费高净资产收益率和低负债的有趣公司名单。
就本文而言,内部人是指向相关监管机构报告其交易的个人。我们目前负责公开市场交易和私人处置,但不包括衍生品交易。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧